Equity Gap are delighted to share that Neurocentrx has successfully completed its latest Phase 1 clinical trial for its novel abuse-deterrent oral ketamine formulation, paving the way for a Phase 2 trial scheduled to launch in early 2026.
Neurocentrx is working towards delivering the first FDA-approved ketamine therapy designed to enable safe, clinician-guided treatment both in-clinic and at home — expanding access for patients who have not responded to existing therapies.
Huge congratulations to the Neurocentrx team, clinical partners, and all trial participants who made this important milestone possible. Onward to Phase 2.